Search - tctmd.com

Displaying 741 - 760 of 991

Sort: Relevancy | Date

News Daily News

TWENTE: los SLF de 2ª Generación tienen Buenos Resultados a Largo Plazo en Lesiones en Bifurcación

L.A. McKeown

November 02, 2014

News Daily News

TWENTE：第二代DES在分叉病变中表现出良好的长期结果

L.A. McKeown

November 02, 2014

News Daily News

Study Confirms Lower Stent Thrombosis, MI Risks With Newer DES

Salynn Boyles

November 02, 2014

News Daily News

DCBs Perform Better in De Novo Compared With Restenotic Femoropopliteal Lesions

Caitlin E. Cox

October 24, 2014

News Conference News TCT 2014

Bioabsorbable Polymer DES Represent Evolution to Stenting Platform

September 19, 2014

Presentation TCT 2014

2-Year Clinical Outcome of the Randomized, Multicenter DUTCH PEERS (TWENTE II) Trial, Comparing Cobalt-Chromium Zotarolimus-Eluting Resolute Integrity Stents and Platinum-Chromi___

Presenter: Clemens von Birgelen

September 16, 2014

Presentation TCT 2014

Three Year Clinical Outcomes of a Unique Sirolimus-Eluting Stent with Fully Absorbable Polymer Coating: Long-term Results from the DESSOLVE I and the DESSOLVE II Clinical Trials_

Presenter: John Ormiston

September 16, 2014

Presentation TCT 2014

TCT 599: Final Procedural, 30-Day and 6-Month Angiographic, Clinical, and OCT Outcomes from the DIRECT II Trial Using the Svelte Integrated Delivery System with Enzymatic Bioabsobable Sirolimus Coating

Presenter: Marie-Claude Morice, Giulio G. Stefanini, Pedro A. Lemos, Stefan Verheye

September 15, 2014

Presentation TCT 2014

RIBS IV: A Prospective, Randomized Trial of Paclitaxel-Eluting Balloons Versus Everolimus-Eluting Stents in Patients with Coronary In-Stent Restenosis of Drug-Eluting Stents

Presenter: Gregg W. Stone, Pieter C. Smits, Fernando Alfonso

September 14, 2014

Presentation TCT 2014

ABSORB II: A Prospective, Randomized Trial of an Everolimus-Eluting Bioresorbable Scaffold Versus an Everolimus-Eluting Metallic Stent in Patients with Coronary Artery Disease

Presenter: Gregg W. Stone, Pieter C. Smits, Patrick W. Serruys

September 14, 2014

News Conference News TCT 2014

ABSORB II: Similar Clinical Outcomes, Less Angina with Bioresorbable Scaffold vs. EES

Yael L. Maxwell

September 14, 2014

News Conference News TCT 2014

Misago BMS Performs Well in Multinational Trial of Patients with SFA Lesions

September 13, 2014

News Conference News TCT 2014

COMPARE II: BES, EES Show Similar Outcomes at Three Years

September 13, 2014

News Conference News ESC 2014

PROTECT: ZES Sustain Lead Over SES at 5 Years

Caitlin E. Cox

September 03, 2014

News Daily News

PROTECT: Menor Riesgo de Trombosis del Stent con el Endeavor a los 4 Años

L.A. McKeown

September 02, 2014

News Daily News

PROTECT: Lower Stent Thrombosis Risk with Endeavor Emerges at 4 Years

L.A. McKeown

September 02, 2014

News Daily News

PROTECT： 4年时采用Endeavor情况下的支架内血栓形成风险更低

L.A. McKeown

September 02, 2014

News Conference News ESC 2014

BIOSCIENCE: Biodegradable Polymer SES Noninferior to Durable Polymer EES in All-Comers Trial

Yael L. Maxwell

September 01, 2014

News Daily News

Study Suggests Noncardiac Surgery Can Be Safe as Early as 3 Months After PCI

Yael L. Maxwell

August 20, 2014

Presentation BRS 2014

Demonstration of Clinical Superiority with a Bioresorbable Vascular Scaffold: The ABSORB III + IV Clinical Trial Program

Presenter: Gregg W. Stone

July 25, 2014

Advertisement

TWENTE: los SLF de 2ª Generación tienen Buenos Resultados a Largo Plazo en Lesiones en Bifurcación

TWENTE：第二代DES在分叉病变中表现出良好的长期结果

Study Confirms Lower Stent Thrombosis, MI Risks With Newer DES

DCBs Perform Better in De Novo Compared With Restenotic Femoropopliteal Lesions

Bioabsorbable Polymer DES Represent Evolution to Stenting Platform

2-Year Clinical Outcome of the Randomized, Multicenter DUTCH PEERS (TWENTE II) Trial, Comparing Cobalt-Chromium Zotarolimus-Eluting Resolute Integrity Stents and Platinum-Chromi___

Three Year Clinical Outcomes of a Unique Sirolimus-Eluting Stent with Fully Absorbable Polymer Coating: Long-term Results from the DESSOLVE I and the DESSOLVE II Clinical Trials_

TCT 599: Final Procedural, 30-Day and 6-Month Angiographic, Clinical, and OCT Outcomes from the DIRECT II Trial Using the Svelte Integrated Delivery System with Enzymatic Bioabsobable Sirolimus Coating

RIBS IV: A Prospective, Randomized Trial of Paclitaxel-Eluting Balloons Versus Everolimus-Eluting Stents in Patients with Coronary In-Stent Restenosis of Drug-Eluting Stents

ABSORB II: A Prospective, Randomized Trial of an Everolimus-Eluting Bioresorbable Scaffold Versus an Everolimus-Eluting Metallic Stent in Patients with Coronary Artery Disease

ABSORB II: Similar Clinical Outcomes, Less Angina with Bioresorbable Scaffold vs. EES

Misago BMS Performs Well in Multinational Trial of Patients with SFA Lesions

COMPARE II: BES, EES Show Similar Outcomes at Three Years

PROTECT: ZES Sustain Lead Over SES at 5 Years

PROTECT: Menor Riesgo de Trombosis del Stent con el Endeavor a los 4 Años

PROTECT: Lower Stent Thrombosis Risk with Endeavor Emerges at 4 Years

PROTECT： 4年时采用Endeavor情况下的支架内血栓形成风险更低

BIOSCIENCE: Biodegradable Polymer SES Noninferior to Durable Polymer EES in All-Comers Trial

Study Suggests Noncardiac Surgery Can Be Safe as Early as 3 Months After PCI

Demonstration of Clinical Superiority with a Bioresorbable Vascular Scaffold: The ABSORB III + IV Clinical Trial Program

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content